Head and Neck Cancer - Pipeline Assessment and Market Forecast to 2017

Head and Neck Cancer Market is Market is Estimated to Roughly Double in Size by
2017

GlobalData expects the global head and neck cancer therapeutics market to grow at a rate
of 7.6% annually for the next seven years to reach $1,854m by 2017. It was valued at
$1,035m in 2009. This significant growth is primarily attributed to the high incidence,
prevalence and diagnosis rate of the disease and the high prescription rates of the
currently approved products. In addition, the successful launch of certain biologics, gene
therapies and vaccines such as Reolysin, OncoVEX and nimotuzumab, currently in Phase
III, may significantly stimulate market growth in the near future. However, the low
treatment seeking rate and the widespread use of off-label drugs will act as barriers for
market growth.

GlobalData’s analysis has found that the current competition in the head and neck cancer
market is weak. The competitive landscape is sparsely populated with only two FDA
(Food and Drug Administration)-approved products. The market is characterized by high
off-label usage of drugs such as cisplatin, paclitaxel carboplatin and combination
therpaies. The currently marketed products are not highly efficacious and so are not able
to meet market demands such as improved five-year survival rates, reductions in tumor
sizes and the control of tumor recurrence. However, the development of technologically
advanced products such as vaccines, gene therapy and biologics in different stages of the
pipeline promises to provide better options for treatment.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Head-and-Neck-Cancer-Drug-
Pipeline-Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti
cals_and_Healthcare

GlobalData has found that there are 405 products in different stages of development.
Reolysin, Oncovex and nimotuzumab, currently in Phase III, are some of the most
promising products in the pipeline. Biologics, gene therapy, vaccines and other molecular
targeted therapies make the pipeline robust enough to meet the unmet needs of the head
and neck cancer market. The pipeline holds novel products which are technologically
advanced and have high efficacy and safety profiles. The efficacy and safety of biologics
such as nimotuzumab (approved in 23 countries and undergoing Phase III studies in the
US) are high in terms of complete response, progression-free survival, improved
tolerability and high safety profiles. Additionally, some of the oncolytic vaccines
currently in Phase III, such as Oncovex, offer systematic benefits by inducing a potent
anti-tumor immune response, as well as the prevention of new lesions and a lowering of
the relapse rate.

GlobalData, the industry analysis specialist’s new report, “Head and Neck Cancer -
Pipeline Assessment and Market Forecast to 2017” is an essential source of information
and analysis on the global head and neck cancer market. The report identifies the key
trends shaping and driving the global head and neck cancer market. The report also
provides insight on the prevalent competitive landscape and the emerging players
expected to bring significant shift in the market positioning of the existing market
leaders. Most importantly, the report provides valuable insight on the pipeline products
within the global head and neck cancer sector. This report is built using data and
information sourced from proprietary databases, primary and secondary research and in
house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Head-and-Neck-Cancer-Drug-
Pipeline-Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti
cals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:

pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782